Sotagliflozin (Inpefa)

Small molecule

Also known as SAR439954

Approvedregulatory verdict

Evidence outlook

Approved: Heart Failure

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Chronic Kidney Disease · Phase 3 · investigational in the USHypertrophic Cardiomyopathy · Phase 3 · investigational in the USType 1 Diabetes · Phase 3 · investigational in the US

Also approved (1)
AE
  • Reduce risk of cardiovascular death, hospitalization for heart failure and urgent heart failure visits in adults with heart failure or T2D, CKD and other cardiovascular risk factors (Inpefa)
biospace.com

Company guidance: regulatory filing expected fourth quarter of 2026 (Lexicon Pharmaceuticals, 6 Aug 2026). “STENO1, a third-party funded, investigator-initiated study of sotagliflozin being conducted by the STENO Diabetes Center (Denmark) is approaching the patient exposure and safety data requirements previously identified by the U.S. Food and Drug Administration (FDA) as being adequate to support a resubmission of the company's New Drug Application (NDA), which Lexicon anticipates will occur in the fourth quarter of 2026 based on current estimated timing of data collection.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (20)
Chronic Kidney Disease
NCT06217302 · Alessandro Doria
2024-10-31 – 2029-05 · Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
What this study did
Heart Failure
Hypertrophic Cardiomyopathy
Type 1 Diabetes
NCT07211802 · University of California, San Diego
2027-04-01 – 2031-12-31 · Type 1 Diabetes (T1D)
What this study did
NCT06082063 · Steno Diabetes Center Copenhagen
2024-07-01 – 2029-07-01 · Cardiovascular Diseases, Heart Failure, Type 1 Diabetes, Kidney Failure
What this study did
Other / comorbidity
NCT03386344 · Lexicon Pharmaceuticals
2018-02-19 – 2020-05-30 · Type 2 Diabetes Mellitus
What this study did
NCT03760965 · Sanofi
2018-11-27 – 2020-04-24 · Type 2 Diabetes Mellitus
What this study did
NCT03332771 · Lexicon Pharmaceuticals
2017-12-01 – 2019-09-06 · Type 2 Diabetes Mellitus
What this study did
NCT03066830 · Lexicon Pharmaceuticals
2017-02-24 – 2019-04-30 · Type 2 Diabetes Mellitus
What this study did
Phase 2 (14)
Chronic Kidney Disease
NCT07594145 · Oregon Health and Science University
2026-11-01 – 2031-12-31 · Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
What this study did
NCT07325201 · HealthPartners Institute
2027-01 – 2030-02 · Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic Ketoacidosis, Ketones
What this study did
NCT06147232 · Steno Diabetes Center Copenhagen
2025-02 – 2027-05 · Nephropathy, Diabetic Nephropathies, Diabetes Mellitus, Type 1, Albuminuria, Diabetic Complications Renal, Diabetic Complications Cardiovascular, Hypoxia
What this study did
Heart Failure
NCT03292653 · Lexicon Pharmaceuticals
2017-12-04 – 2019-08-17 · Cardiac Failure Aggravated
What this study did
Type 1 Diabetes
NCT07421518 · AdventHealth Translational Research Institute
2026-06 – 2030-04 · Type 1 Diabetes, Type 2 Diabetes
What this study did
NCT06435156 · University of Dundee
2025-01-28 – 2027-10-31 · Type 1 Diabetes, Heart Failure
What this study did
NCT02383940 · Lexicon Pharmaceuticals
2015-04 – 2016-09 · Type 1 Diabetes Mellitus
What this study did
NCT02459899 · Lexicon Pharmaceuticals
2015-07 – 2016-08 · Type 1 Diabetes Mellitus
What this study did
NCT01742208 · Lexicon Pharmaceuticals
2013-02 – 2014-01 · Type 1 Diabetes Mellitus
What this study did
Other / comorbidity
NCT07572175 · Icahn School of Medicine at Mount Sinai
2026-07 – 2029-10 · Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
What this study did
NCT05405556 · Martina McGrath, MD
2022-10-17 – 2024-11-16 · Kidney Transplant
What this study did
NCT03462069 · Sanofi
2018-03-12 – 2019-04-18 · Diabetes Mellitus
What this study did
NCT01376557 · Lexicon Pharmaceuticals
2011-06 – 2012-05 · Type 2 Diabetes Mellitus
What this study did
NCT00962065 · Lexicon Pharmaceuticals
2009-08 – 2009-12 · Type 2 Diabetes Mellitus
What this study did
Phase 1/2 (1)
Type 1 Diabetes
NCT05696366 · University of California, San Diego
2024-09-09 – 2028-01 · Type 1 Diabetes
What this study did
Phase 1 (28)
Hypertrophic Cardiomyopathy
NCT06433050 · University of Pennsylvania
2024-12-17 – 2027-06 · Hypertrophic Cardiomyopathy Without Obstruction
What this study did
Type 1 Diabetes
NCT03310944 · Sanofi
2017-10-18 – 2017-12-08 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT06933056 · University of Michigan
2025-09-02 – 2026-10-19 · Platelet Function and Reactivity Tests
What this study did
NCT03909451 · Sanofi
2019-04-28 – 2019-08-19 · Diabetes Mellitus
What this study did
NCT03776227 · Sanofi
2019-01-25 – 2019-04-22 · Type 2 Diabetes Mellitus, Healthy Subjects
What this study did
NCT03802487 · Sanofi
2019-01-14 – 2019-03-28 · Type 2 Diabetes Mellitus, Healthy Subjects
What this study did
NCT03414723 · Sanofi
2018-01-15 – 2018-03-10 · Diabetes Mellitus, Healthy Subjects
What this study did
NCT03387657 · Sanofi
2018-01-03 – 2018-03-02 · Type 2 Diabetes Mellitus
What this study did
NCT02647918 · Lexicon Pharmaceuticals
2015-12 – 2017-09 · Renal Impairment, Healthy
What this study did
NCT03211195 · Sanofi
2017-06-29 – 2017-08-22 · Type 2 Diabetes Mellitus
What this study did
NCT03063580 · Sanofi
2017-02-27 – 2017-05-12 · Diabetes Mellitus
What this study did
NCT02940379 · Sanofi
2016-10 – 2016-12 · Type 2 Diabetes Mellitus
What this study did
NCT02471274 · Lexicon Pharmaceuticals
2015-06 – 2015-12 · Hepatic Impairment, Healthy
What this study did
NCT02494609 · Lexicon Pharmaceuticals
2015-07 – 2015-11 · Healthy
What this study did
NCT02373046 · Lexicon Pharmaceuticals
2015-02 – 2015-04 · Healthy
What this study did
NCT02300350 · Lexicon Pharmaceuticals
2014-10 – 2014-12 · Healthy
What this study did
NCT02300363 · Lexicon Pharmaceuticals
2014-10 – 2014-11 · Healthy
What this study did
NCT01916863 · Lexicon Pharmaceuticals
2013-08 – 2013-10 · Healthy Subjects
What this study did
NCT01916850 · Lexicon Pharmaceuticals
2013-08 – 2013-10 · Healthy
What this study did
NCT01913002 · Lexicon Pharmaceuticals
2013-07 – 2013-10 · Healthy
What this study did
NCT01555008 · Lexicon Pharmaceuticals
2012-03 – 2013-08 · Type 2 Diabetes Mellitus, Renal Impairment
What this study did
NCT01818232 · Lexicon Pharmaceuticals
2013-03 – 2013-05 · Healthy
What this study did
NCT01441232 · Lexicon Pharmaceuticals
2011-10 – 2011-11 · Type 2 Diabetes Mellitus
What this study did
NCT01334242 · Lexicon Pharmaceuticals
2011-03 – 2011-04 · Healthy
What this study did
NCT01292993 · Lexicon Pharmaceuticals
2011-02 – 2011-03 · Type 2 Diabetes Mellitus
What this study did
NCT01188863 · Lexicon Pharmaceuticals
2010-09 – 2010-10 · Type 2 Diabetes Mellitus
What this study did
Phase 4 (4)
Chronic Kidney Disease
NCT07547878 · Baylor Research Institute
2026-04-08 – 2029-03-31 · Chronic Kidney Disease, Type 2 Diabetes
What this study did
Heart Failure
NCT05562063 · Juan Badimon
2022-10-26 – 2025-06-04 · Heart Failure With Preserved Ejection Fraction
What this study did
Other / comorbidity
NCT07939750 · Allied Hospital Faisalabad
2026-12-01 – 2028-01-31 · Type 2 Diabetes Mellitus (DM)
What this study did
NCT06618976 · Icahn School of Medicine at Mount Sinai
2025-02-25 – 2026-02-10 · Thrombosis
What this study did

Competitive landscape

This drug's own stage for Chronic Kidney Disease: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sotagliflozin (Inpefa): this drugPhase 3Small moleculeSGLT1/2 (dual)Partial signal
NCT03242018: Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo (Baseline to Week 26): Sotagliflozin 400 mg -0.4 percentage of HbA1c (Standard Error 0.131) vs Placebo -0.11 percentage of HbA1c (Standard Error 0.151) missed
NCT03242252: Change From Baseline in HbA1c at Week 26 (Baseline to Week 26): Sotagliflozin 200 mg -0.32 percentage of HbA1c (Standard Error 0.06) | Sotagliflozin 400 mg -0.46 percentage of HbA1c (Standard Error 0.06) vs Placebo -0.22 percentage of HbA1c (Standard Error 0.061)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Reliable signal
NCT03436693: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029)
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT03036150: Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001
Difelikefalin (Korsuva)ApprovedPeptideKappa-opioid receptor (agonist, peripherally restricted)Reliable signal
NCT03636269: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 (Week 12): CR845 0.5mcg/kg 54% (95% CI 43.9 to 63.9) vs Placebo 42.2% (95% CI 32.5 to 52.5)
NCT03422653: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 (Week 12): CR845 0.5mcg/kg 51% (95% CI 42.9 to 58.9) vs Placebo 27.6% (95% CI 20.2 to 36.6)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03594110: Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met.
NCT05373680: Adjusted mean difference in eGFR decline vs standard-of-care control: metformin +8.91 ± 1.92 (p<0.001); empagliflozin +5.1 ± 1.89 (p=0.03) — both halted CKD progression vs control.
Etelcalcetide (Parsabiv)ApprovedPeptideCalcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cellsPartial signal
NCT01785849: Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).): Etelcalcetide 74% vs Placebo 8.3%
NCT01788046: Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).): Etelcalcetide 75.3% vs Placebo 9.6%
Extended-Release Calcifediol (Rayaldee)ApprovedSmall moleculeVitamin D receptor (VDR), via conversion to calcitriolPartial signal
NCT01704079: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline (Approximately 6 months): CTAP101 30 μg Capsules 49/144 (34.0%) vs Sugar Pill to CTAP101 30 μg 5/72 (6.9%)
NCT01651000: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values (Approximately 6 months): CTAP101 30 μg Capsules 46/141 (32.6%) vs Sugar Pill to CTAP101 30 μg Capsule 6/72 (8.3%)
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT00317239: Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL (anytime during the study): Ferric Carboxymaltose (FCM) 87/144 vs Ferrous Sulfate Tablets 35/101
Ferric Derisomaltose (Monoferric / Monofer)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT02940860: Change in Hemoglobin (Hb) From Baseline to Week 8 (Baseline to week 8): Iron Isomaltoside/Ferric Derisomaltose 1.22 g/dL (95% CI 1.14 to 1.31) vs Iron Sucrose 1.14 g/dL (95% CI 1.03 to 1.26)
NCT01102413: Change in Hemoglobin (Hb) Concentration From Baseline to Week 4. (Baseline, 4 weeks): Monofer 0.57 g/dL (range -3.1 to 4) vs Iron Sulphate 0.35 g/dL (range -3.7 to 3.9)
Ferric Pyrophosphate Citrate (Triferic)
ApprovedUS marketing discontinued
Small moleculeIron-replacement therapy delivered via dialysateWeak signalNo reviewed efficacy summary in this indication
Ferumoxytol (Feraheme)ApprovedNanoparticleIV iron replacement therapyPartial signal
NCT00255424: Primary endpoint (hemoglobin change at day 35): ferumoxytol +0.82 ± 1.24 g/dl vs oral iron +0.16 ± 1.02 g/dl, P<0.0001, in favor of ferumoxytol. CT.gov's own citation list ties this Spinowitz 2008 publication specifically to NCT00255424 (not its twin trial NCT00255437).
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT05047263: Total eGFR slope, baseline to month 32 (FIND-CKD): -3.3 mL/min/1.73m2/year finerenone vs -4.0 mL/min/1.73m2/year placebo; between-group difference 0.7 mL/min/1.73m2/year (95% CI 0.3-1.1; p<0.001)
NCT02540993: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death (From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months): Finerenone 504/2833 vs Placebo 600/2841
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
Sucroferric Oxyhydroxide (Velphoro)ApprovedSmall moleculeDietary phosphatePartial signal
NCT03644264: Change in serum phosphorus from baseline to week 12: -0.71 (0.60) mmol/L with sucroferric oxyhydroxide vs -0.63 (0.52) mmol/L with sevelamer; difference in least squares means 0.08 mmol/L (95% CI -0.02, 0.18), meeting the pre-specified non-inferiority margin of -0.34 mmol/L
NCT01464190: Change From Baseline and Levels at Each Time Point for Serum Phosphorus (Every 4 weeks from baseline to Week 28): PA21 — Change from Baseline to Week 4 (n = 346, 236): -0.2 mg/dL (Standard Deviation 1.33); Change from Baseline to Week 8 (n = 325, 238): -0.2 mg/dL (Standard Deviation 1.38); Change from Baseline to Week 12 (n = 322, 242): 0 mg/dL (Standard Deviation 1.43); Change from Baseline to Week 16 (n = 313, 228): 0 mg/dL (Standard Deviation 1.57); Change from Baseline to Week 20 (n = 300, 221): 0 mg/dL (Standard Deviation 1.46); Change from Baseline to Week 24 (n = 286, 208): 0.1 mg/dL (Standard Deviation 1.53); Chnage from Baseline to Week 28 (n = 287, 210): 0.2 mg/dL (Standard Deviation 1.52); Change from Baseline to Endpoint (n = 384, 260): 0.1 mg/dL (Standard Deviation 1.62) vs Sevelamer Carbonate — Change from Baseline to Week 4 (n = 346, 236): -0.1 mg/dL (Standard Deviation 1.47); Change from Baseline to Week 8 (n = 325, 238): 0.1 mg/dL (Standard Deviation 1.56); Change from Baseline to Week 12 (n = 322, 242): 0.2 mg/dL (Standard Deviation 1.55); Change from Baseline to Week 16 (n = 313, 228): 0.2 mg/dL (Standard Deviation 1.75); Change from Baseline to Week 20 (n = 300, 221): 0.1 mg/dL (Standard Deviation 1.44); Change from Baseline to Week 24 (n = 286, 208): 0.2 mg/dL (Standard Deviation 1.78); Chnage from Baseline to Week 28 (n = 287, 210): 0.2 mg/dL (Standard Deviation 1.76); Change from Baseline to Endpoint (n = 384, 260): 0.3 mg/dL (Standard Deviation 1.79)
Taurolidine / Heparin (Defencath / Neutrolin)ApprovedSmall moleculeAntimicrobial/antithrombotic catheter lock solutionReliable signal
NCT02651428: Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD): Final Analysis (The event time was the number of days from randomization until the occurrence of a CAC-Adjudicated CRBSI or until the subject was censored. The mean participant duration of exposure to study drug was 174 days (range 4-884 days).): Neutrolin Arm 9/397 vs Heparin Arm 32/398
Tenapanor (Xphozah)ApprovedSmall moleculeNHE3 (sodium/hydrogen exchanger isoform 3)Partial signal
NCT03427125: Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder Population (12 weeks (randomized withdrawal period)): Tenapanor 10 mg, 20 mg, 30 mg BID 0.43 mg/dL (Standard Deviation 0.199) | Placebo 1.8 mg/dL (Standard Deviation 0.196)
NCT02675998: Primary 4-week randomized-withdrawal serum phosphate change: pooled tenapanor 1.4 mg/dL vs placebo 0.6 mg/dL (p=0.01).
Vadadustat (Vafseo)ApprovedSmall moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT02680574: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 0.41 Grams per deciliter (g/dL) (Standard Error 0.036) vs Darbepoetin Alfa 0.42 Grams per deciliter (g/dL) (Standard Error 0.037)
NCT02648347: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 1.43 g/dL (Standard Error 0.046) vs Darbepoetin Alfa 1.38 g/dL (Standard Error 0.047)
AND017Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signalNo reviewed efficacy summary in this indication
Anrikefon (HSK21542)Phase 3PeptideKappa-opioid receptor (agonist, peripherally restricted)Reliable signal
NCT05135390: Proportion with ≥4-point WI-NRS improvement at week 12: anrikefon 37% vs placebo 15% (P<0.001)
AP301 (fiber-Iron Phosphate Binder)Phase 3Small moleculeIron-based intestinal phosphate binderPartial signal
NCT07030595: Primary 1, serum phosphate change baseline to week 12, AP301 vs sevelamer carbonate (non-inferiority, margin 0.19 mmol/L): LSM difference -0.02 mmol/L (95% CI -0.10 to 0.06), upper bound below margin, met. Primary 2, serum phosphate change week 24 to week 27, AP301 maintenance dose vs low dose: LSM difference -0.58 mmol/L (95% CI -0.69 to -0.47; P<0.001), equivalent to -1.8 mg/dL, met.
ApecotrepPhase 3Small moleculeTRPC6 (transient receptor potential cation channel subfamily C member 6)Partial signal
NCT05213624: Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 (At baseline and Week 12.): BI 764198 20 mg 48.9 Predicted percentage of patients (95% CI 29.2 to 68.6) | BI 764198 40 mg 16 Predicted percentage of patients (95% CI -1.5 to 33.5) | BI 764198 80 mg 38.5 Predicted percentage of patients (95% CI 12.2 to 64.8) vs Placebo 11.4 Predicted percentage of patients (95% CI -2.3 to 25.2)
NCT04176536: Single 40mg dose, matched-pair renal-impairment vs normal-renal-function design (NCT04176536): AUC increased 48% (moderate) / 78% (severe) renal impairment vs healthy controls; Cmax increased 14% / 12%; terminal half-life 12.7-17.4h independent of dose and renal function.
AST-120 (Kremezin)Phase 3Small moleculeOral spherical carbon adsorbentPartial signal
NCT00500682: Primary endpoint, time to composite of dialysis initiation, kidney transplantation or serum creatinine doubling: hazard ratio 1.03 (95% CI 0.84 to 1.27), P=0.78; events AST-120 178/500 vs placebo 177/502. missed
NCT00501046: Primary endpoint, time to composite of dialysis initiation, kidney transplantation or serum creatinine doubling: hazard ratio 0.91 (95% CI 0.74 to 1.12), P=0.37; events AST-120 172/500 vs placebo 183/497. missed
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signal
NCT04595370: Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): AZD9977 15 mg + Dapagliflozin 10 mg -56.391% (95% CI -71.528--33.207) vs AZD9977 50 mg + Dapagliflozin 10 mg -42.085% (95% CI -64.174--6.376) vs AZD9977 150 mg + Dapagliflozin 10 mg -58.047% (95% CI -73.560--33.430) vs AZD9977 150 mg -45.01% (95% CI NA-NA) vs Dapagliflozin 10 mg -34.318% (95% CI -58.204-3.220) vs Placebo 230.32% (95% CI NA-NA); p=0.3645 (AZD9977 15 mg + Dapagliflozin 10 mg vs AZD9977 50 mg + Dapagliflozin 10 mg vs AZD9977 150 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg) missed
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
BHV-1400Phase 3Biologic (subtype unspecified)Gd-IgA1 (galactose-deficient IgA1)not yet gradedNo reviewed efficacy summary in this indication
Bixalomer (Kiklin)Phase 3Small moleculePhosphate binderWeak signal
NCT01742585: Change in serum phosphorus, baseline to end of treatment (12 weeks): bixalomer -0.78 mg/dL (95% CI -0.98, -0.57) vs placebo 0.20 mg/dL (95% CI -0.00, 0.41); mean difference -0.98 mg/dL (95% CI -1.27, -0.69), P < 0.001.
NCT01742611: Mean serum phosphorus: 5.15 mg/dL at baseline, decreasing to 4.67 mg/dL at Week 12, reaching 4.58 mg/dL at Week 48 of open-label bixalomer treatment
Colestilan (Cholebine / BindRen)Phase 3Small moleculePhosphate binderPartial signal
NCT00542815: Primary outcome, change in serum phosphorus from baseline to week 52 in an open-label long-term safety study (no comparator test): -1.23 mg/dL (colestilan from E07/E08), -1.47 mg/dL (colestilan from E07) and -2.26 mg/dL (sevelamer from E07) (CT.gov posted results).
NCT00416520: Serum phosphorus at week 16 (end of the 4-week placebo-controlled withdrawal): 0.43 mmol/L (1.32 mg/dL) lower with colestilan than with placebo (P<0.001) (Locatelli et al., Nephrol Dial Transplant 2014).
Desidustat (Oxemia)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT04215120: Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382)
NCT04012957: Change in hemoglobin baseline to week 16-24: desidustat +1.95 g/dL vs darbepoetin +1.83 g/dL (difference 0.11 g/dL, 95% CI -0.12 to 0.34), met prespecified noninferiority margin of -0.75 g/dL; hemoglobin responders 77.78% desidustat vs 68.48% darbepoetin (p=0.0181)
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
EnarodustatPhase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT06016036: Mean Hb change from baseline averaged over Weeks 7-9: enarodustat +15.99 g/L (SD 9.46) vs placebo +0.14 g/L (SD 8.08); P<0.001
NCT04027517: 평가기간 중 투여군간 차이 [95% 신뢰구간] -0.19 [-0.46, 0.08] (이 약 투여군 N=57 평가기간 중 Hb 농도 평균 10.65 g/dL, 다베포에틴 알파 투여군 N=67 10.83 g/dL; 베이스라인 10.73 vs 10.68 g/dL; 비열등성 마진 -1.0 g/dL)
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
HRS-1780Phase 3Small moleculeMineralocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Imlifidase (Idefirix)Phase 3Protein / enzyme therapeuticImmunoglobulin G (IgG), all four human subclassesWeak signal
NCT02790437: Crossmatch conversion (positive to negative) within 24 hours of IdeS dosing: 17 of 19 patients converted; 2 of 19 did not.
Iptacopan (Fabhalta)Phase 3Small moleculeComplement Factor BPartial signal
NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met.
NCT03373461: MCP-Mod Estimates of the Ratio to Baseline of Urine Protein to Creatinine Ratio (UPCR) (g/Mol) - Parts 1 and 2 at Day 90 (Baseline and Day 90): LNP023 10 mg BID 0.85 Ratio to baseline (95% CI 0.77-0.93) vs LNP023 50 mg BID 0.80 Ratio to baseline (95% CI 0.73-0.87) vs LNP023 100 mg BID - Part 2 0.76 Ratio to baseline (95% CI 0.70-0.81) vs LNP023 200 mg BID 0.69 Ratio to baseline (95% CI 0.61-0.77) vs Placebo 0.88 Ratio to baseline (95% CI 0.80-1.00); p=0.038 (LNP023 10 mg BID vs LNP023 50 mg BID vs LNP023 100 mg BID - Part 2 vs LNP023 200 mg BID vs Placebo)
JR-131Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signal
NCT02912494: Change in Hb level from baseline to end of treatment (24 weeks): JR-131 −0.42 ± 0.73 g/dL vs darbepoetin alfa −0.43 ± 0.77 g/dL; between-group difference 0.01 g/dL (95% CI −0.19 to 0.20), within the prespecified equivalence margin of −0.5 to 0.5 g/dL
Loncipoetin Alfa (NuPIAO)Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signal
NCT05211167: Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given.
MezagitamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
MolidustatPhase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT03543657: Mean Hb during evaluation period (weeks 33-36): molidustat 10.63 g/dL (95% CI 10.42-10.84) vs darbepoetin alfa 10.77 g/dL (95% CI 10.59-10.95); LS mean difference -0.13 g/dL (95% CI -0.46 to 0.19); noninferiority (margin 1.0 g/dL) established
NCT03350347: Mean Hb during the week 30-36 evaluation period: 11.67 g/dL molidustat vs 11.53 g/dL darbepoetin; LS mean difference 0.13 g/dL (95% CI -0.15 to 0.40), inside the 1.0 g/dL noninferiority margin.
MT1013Phase 3PeptideCaSR; OGPPartial signalNo reviewed efficacy summary in this indication
NNG-DEPO (Stimus)Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signalNo reviewed efficacy summary in this indication
Patiromer (Veltassa)Phase 3Small moleculeGastrointestinal potassium binderPartial signal
NCT01810939: Change in Serum Potassium From Part A Baseline to Part A Week 4 (Part A Baseline to Part A Week 4): Part A Patiromer -1.01 mEq/L (Standard Error 0.031)
Pegmolesatide (HS-20039)Phase 3PeptideErythropoietin receptor (EPO-R)Reliable signal
NCT03903809: Mean Hb change from baseline: pegmolesatide +19.2 g/L vs epoetin alfa +15.4 g/L; between-group difference 3.8 g/L (95% CI 0.7-6.9), noninferiority margin -10 g/L
NCT03902691: Mean change in hemoglobin (baseline to evaluation period): +0.07 g/dL pegmolesatide vs -0.22 g/dL epoetin alfa; between-group difference 0.29 g/dL (95% CI 0.11-0.47), non-inferiority verified
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
Rilparencel (Neo-Kidney Augment / REACT)Phase 3Cell therapySelected renal cells (autologous, paracrine)Weak signal
NCT05018416: Primary endpoint (difference in annual eGFR slope, pre- vs post-treatment): Group 1 (n=24) -5.8 to -1.3 mL/min/1.73m2, difference 4.6 per year, 78% improvement, P < .001; Group 2 (n=25) -3.4 to -1.7 mL/min/1.73m2, difference 1.7 per year, 50% improvement, P = .085
Roxadustat (Evrenzo)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Reliable signal
NCT01750190: Mean hemoglobin change over Weeks 28-52: 2.00 g/dL roxadustat vs 0.16 g/dL placebo; least-squares mean difference 1.85 g/dL (95% CI 1.735-1.967; p<0.0001). Hemoglobin response during the first 24 weeks: 523/608 roxadustat vs 20/305 placebo; odds ratio 77.56 (95% CI 44.73-134.48; p<0.0001).
NCT01887600: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response (Baseline to week 24): Roxadustat 79.2% (95% CI 74.8 to 83.1) vs Placebo 9.9% (95% CI 6.1 to 14.8)
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
SC0062Phase 3Small moleculeEndothelin receptor type A (ETA)not yet gradedNo reviewed efficacy summary in this indication
SHR6508Phase 3Small moleculeCalcium-sensing receptor (CaSR)Weak signalNo reviewed efficacy summary in this indication
Sodium Zirconium Cyclosilicate (Lokelma)Phase 3Small moleculeGastrointestinal potassium binderPartial signal
NCT05056727: Total eGFR Slope (Coprimary Analysis #1) (Baseline (Maintenance phase) to visit 17 (week 69)): Maintenance Phase: SZC -5.2975 mL/min/(1.73 m2)/yr (95% CI -6.6854 to -3.9097) vs Maintenance Phase: Placebo -4.5622 mL/min/(1.73 m2)/yr (95% CI -5.9969 to -3.1275) missed
Somatropin (Jintropin)Phase 3Biologic (subtype unspecified)Growth hormone receptorPartial signal
NCT03535415: HT-SDS change at week 52: +0.75 (rhGH-treated) vs +0.17 (untreated control), reported as statistically significant; enrollment (68) and design match NCT03535415 exactly, and the paper is indexed against this NCT.
Upacicalcet (UPASITA)Phase 3Small moleculeCalcium-sensing receptor (CaSR)Partial signal
NCT05836220: PATH-2, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 43.5% versus 17.4%, for a difference in proportions of 26.1% (95% confidence interval, 17.4 to 34.8, P < 0.001) (J Am Soc Nephrol, 2026-10-23).
NCT05832931: PATH-1, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 42.1% versus 16.8%, for a difference in proportions of 25.3% (95% confidence interval, 16.2 to 34.5, P < 0.001) (J Am Soc Nephrol, 2026-10-23).
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)Partial signal
NCT06531824: Discontinued by Boehringer Ingelheim on an independent Data Monitoring Committee recommendation: accumulating data did not support a meaningful expectation of benefit on the primary composite endpoint vs empagliflozin alone (September 2026). missed
NCT05182840: Change in log UACR at week 14 (all patients): 10 mg -0.553 vs placebo -0.066 (difference -0.486, 95% CI -0.660 to -0.313, p<0.0001); 20 mg -0.487 (difference -0.421, 95% CI -0.596 to -0.246, p<0.0001); 3 mg -0.235 (difference -0.168, 95% CI -0.337 to -0.000, p=0.0499). Adjusted median percent change: 10 mg -42.5% vs placebo -6.4%.
Zibotentan + DapagliflozinPhase 3Small moleculeEndothelin A receptor, SGLT2not yet gradedNo reviewed efficacy summary in this indication
ZigakibartPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
InaxaplinPhase 2/3Small moleculeAPOL1 (Apolipoprotein L1)Weak signal
NCT06794996: Single-group Phase 2b AMPLIFIED: UACR -42.7% (cohort 1) and -17.3% (AMKD with type 2 diabetes) from baseline at Week 13 (Vertex, 2026-09-22).
NCT04340362: The primary outcome was the percent change from the baseline urinary protein-to-creatinine ratio at week 13 in participants with at least 80% adherence to inaxaplin therapy. Sixteen participants were enrolled; among the 13 who were treated and met the adherence threshold, the mean change from baseline at week 13 was -47.6% (95% confidence interval, -60.0 to -31.3).
KT-301Phase 2/3Microbiome therapeuticProbiotic live biotherapeuticnot yet gradedNo reviewed efficacy summary in this indication
AB002Phase 2Protein / enzyme therapeuticProtein CPartial signal
NCT03963895: Primary outcomes: 40 registered safety and tolerability counts (treatment-related adverse events, access-site bleeding, ECG, anti-thrombin antibodies, vital signs and laboratory changes); safety outcome, no formal efficacy test. Treatment-related TEAEs: 0 in each AB002 dose group and 0 with placebo (CT.gov posted results).
ALN-ANG3Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
Avacopan (Tavneos)Phase 2Small moleculeComplement C5a receptor 1 (C5aR1/CD88)Weak signalFeatured results are pharmacokinetic only in this race
CagrilintidePhase 2PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Partial signalNo reviewed efficacy summary in this indication
QiShenYiQiPhase 2BotanicalTraditional Chinese medicine (multi-component)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Samsca)Phase 2Small moleculeVasopressin V2 receptornot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 37 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sotagliflozin (Inpefa) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (5)
January 2027 (1)
Phase 3Hypertrophic CardiomyopathyActive not recruiting
Est. primary completion 2027-01 · NCT06481891 · CT.gov ↗
What to watch
May 2027 (2)
Phase 1Hypertrophic CardiomyopathyActive not recruiting
Est. primary completion 2027-05 · NCT06433050 · CT.gov ↗
What to watch
Phase 2Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-05 · NCT06147232 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Heart FailureRecruiting
Est. primary completion 2027-10-31 · NCT06435156 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4Type 2 Diabetes Mellitus (DM)Not yet recruiting
Est. primary completion 2027-12-01 · NCT07939750 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Phase 1/2Type 1 DiabetesActive not recruiting
Est. primary completion 2028-01 · NCT05696366 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Heart FailureRecruiting
Est. primary completion 2028-12 · NCT06217302 · CT.gov ↗
What to watch
2029 (5)
February 2029 (1)
Phase 2Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2029-02 · NCT07325201 · CT.gov ↗
What to watch
March 2029 (1)
Phase 4Chronic Kidney DiseaseEnrolling by invitation
Est. primary completion 2029-03-31 · NCT07547878 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, CardiotoxicityNot yet recruiting
Est. primary completion 2029-06 · NCT07572175 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Heart FailureRecruiting
Est. primary completion 2029-07-01 · NCT06082063 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Heart FailureNot yet recruiting
Est. primary completion 2029-12-31 · NCT07594145 · CT.gov ↗
What to watch
2030 (1)
April 2030 (1)
Phase 2Type 1 DiabetesNot yet recruiting
Est. primary completion 2030-04 · NCT07421518 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 3Type 1 DiabetesNot yet recruiting
Est. primary completion 2031-07-31 · NCT07211802 · CT.gov ↗
What to watch

See the full readout calendar ↗